FDA Brief

Warning letters Devices

FDA warning letter to

Becton, Dickinson, and Company/CareFusion 303, Inc.

High riskIssued Nov 22, 2024Posted Dec 17, 2024Center for Devices and Radiological Health

FDA warned Becton Dickinson/CareFusion over Pyxis medication dispensing systems with unresolved software defects, missed MDR reports and unreported recalls.

What happened

FDA inspected the firm's San Diego, California facility from May 6 through May 22, 2024. Investigators found 544 open software defect tickets for the Pyxis systems (111 of them classed as catastrophic or severe patient harm), complaints that were never evaluated for reporting to FDA, and device reports to FDA that arrived far past the 30-day deadline. FDA also found that three customer notifications correcting potentially risky problems were never reported to the agency as corrections or removals.

What FDA found

  1. The firm did not have working procedures to fix problems and prevent them from recurring, leaving hundreds of software defect tickets open, some tied to severe patient harm.

    21 CFR 820.100(a)
  2. Complaints were not received, reviewed and evaluated by a formally designated unit, and about 92,083 complaints of delayed medication delivery and 70 of wrong medication dispensed showed no evidence of investigation.

    21 CFR 820.198(a)
  3. Design validation did not adequately analyze risk, because the hazard analysis for MedStation ES left out higher-severity risks such as a reported patient death from delayed access to medications and other life-threatening events.

    21 CFR 820.30(g)
  4. The firm failed to report device malfunctions to FDA within 30 calendar days of learning about them, including unexpected reboots, missing patient data, drawer inaccessibility and MedBank units emitting smoke or a burning smell.

    21 CFR 803.50(a)(2)
  5. The firm did not submit reports of correction or removal within 10 working days for actions taken to fix problems that may present a risk to health, such as door/drawer failures, a MedStation ES software update and a MedBank software update.

    21 CFR 806.10

What FDA wants

FDA tells the firm to write back within 15 business days describing the specific steps taken to fix the violations, how it will prevent them from recurring, and a timetable for any actions that will take longer.

Who should pay attention

  • hospitals and health systems using Pyxis automated dispensing cabinets
  • medical device and software makers with complaint handling and MDR obligations
  • companies that acquire, service or integrate with medication dispensing systems

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  2. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  3. O.N. Diagnostics, LLC

    FDA says O.N. Diagnostics sold changed VirtuOst VFA software without required clearance and had quality and reporting failures.

    High risk
  4. Lion Street Medical, d/b/a Pensar Medical LLC

    FDA warns Pensar Medical over unreported wound-therapy injuries and missing device reporting procedures.

    High risk